Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1989 May;27(5):843–848. doi: 10.1128/jcm.27.5.843-848.1989

Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24.

G Schmidt 1, K Amiraian 1, H Frey 1, J Wethers 1, R W Stevens 1, D S Berns 1
PMCID: PMC267441  PMID: 2501350

Abstract

Antibody responses of 85 patients to human immunodeficiency virus type 1 antigens were quantitated by densitometric analysis of Western blot (immunoblot) assays. All patients had been classified into the following three clinical categories: asymptomatic (ASY), acquired immunodeficiency syndrome (AIDS)-related complex (ARC), or AIDS. Fifty of the patients were monitored for 6 to 29 months. The gp41/p24 antibody ratio was examined in three studies. In the first study, initial specimens from each patient were analyzed. The mean gp41/p24 antibody ratios were 1.5 (ASY), 3.2 (ARC), and 5.4 (AIDS). Of ASY patients, 79% had antibody ratios of less than 2.0. In contrast, 72% of patients with AIDS had ratios of greater than or equal to 2.0. In the second study, serially obtained specimens from ASY, ARC, and AIDS patients were analyzed. These patients were further grouped according to progression of their clinical condition. Of ASY patients whose clinical condition progressed to ARC, 80% consistently had ratios of greater than or equal to 2.0. Of ARC patients whose clinical condition progressed to AIDS, 71% consistently had ratios of greater than or equal to 2.0. Of AIDS patients who died during the study, 100% consistently had ratios of greater than or equal to 2.0. No patients were treated with azidothymidine during the first two studies. In the third study, AIDS patients were monitored before and during treatment with azidothymidine. During treatment, ratios stabilized or improved transiently in five of seven patients. In these three studies, a gp41/p24 antibody ratio of less than 2.0 correlated with a benign clinical state and a ratio of greater than or equal to 2.0 correlated with AIDS or progression to AIDS.

Full text

PDF
843

Images in this article

845Image
on p.845

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abb J. Evaluation of a new confirmatory assay for antibodies against lymphadenopathy-associated virus (LAV)/human T-lymphotropic virus type III (HTLV III). Vox Sang. 1986;51(3):233–235. doi: 10.1111/j.1423-0410.1986.tb01960.x. [DOI] [PubMed] [Google Scholar]
  2. Allain J. P., Laurian Y., Paul D. A., Senn D. Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. Lancet. 1986 Nov 29;2(8518):1233–1236. doi: 10.1016/s0140-6736(86)92673-5. [DOI] [PubMed] [Google Scholar]
  3. Barin F., McLane M. F., Allan J. S., Lee T. H., Groopman J. E., Essex M. Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science. 1985 May 31;228(4703):1094–1096. doi: 10.1126/science.2986291. [DOI] [PubMed] [Google Scholar]
  4. Biggar R. J., Melbye M., Ebbesen P., Alexander S., Nielsen J. O., Sarin P., Faber V. Variation in human T lymphotropic virus III (HTLV-III) antibodies in homosexual men: decline before onset of illness related to acquired immune deficiency syndrome (AIDS). Br Med J (Clin Res Ed) 1985 Oct 12;291(6501):997–998. doi: 10.1136/bmj.291.6501.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blanche S., Le Deist F., Fischer A., Veber F., Debre M., Chamaret S., Montagnier L., Griscelli C. Longitudinal study of 18 children with perinatal LAV/HTLV III infection: attempt at prognostic evaluation. J Pediatr. 1986 Dec;109(6):965–970. doi: 10.1016/s0022-3476(86)80277-3. [DOI] [PubMed] [Google Scholar]
  6. Blomberg J., Klasse P. J. Quantification of immunoglobulin on electrophoretic immunoblot strips as a tool for human immunodeficiency virus serodiagnosis. J Clin Microbiol. 1988 Jan;26(1):111–115. doi: 10.1128/jcm.26.1.111-115.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Burke D. S., Redfield R. R., Putman P., Alexander S. S. Variations in Western blot banding patterns of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. J Clin Microbiol. 1987 Jan;25(1):81–84. doi: 10.1128/jcm.25.1.81-84.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. DeVico A. L., Veronese F. D., Lee S. L., Gallo R. C., Sarngadharan M. G. High prevalence of serum antibodies to reverse transcriptase in HIV-1-infected individuals. AIDS Res Hum Retroviruses. 1988 Feb;4(1):17–22. doi: 10.1089/aid.1988.4.17. [DOI] [PubMed] [Google Scholar]
  9. Des Jarlais D. C., Friedman S. R., Spira T. J., Zolla-Pazner S., Marmor M., Holzman R., Mildvan D., Yancovitz S., Mathur-Wagh U., Garber J. A stage model of HTLV-III LAV infection in intravenous drug users. NIDA Res Monogr. 1986;67:328–334. [PubMed] [Google Scholar]
  10. Fauci A. S., Macher A. M., Longo D. L., Lane H. C., Rook A. H., Masur H., Gelmann E. P. NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med. 1984 Jan;100(1):92–106. doi: 10.7326/0003-4819-100-1-92. [DOI] [PubMed] [Google Scholar]
  11. Gottlieb M. S., Schroff R., Schanker H. M., Weisman J. D., Fan P. T., Wolf R. A., Saxon A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981 Dec 10;305(24):1425–1431. doi: 10.1056/NEJM198112103052401. [DOI] [PubMed] [Google Scholar]
  12. Groopman J. E., Chen F. W., Hope J. A., Andrews J. M., Swift R. L., Benton C. V., Sullivan J. L., Volberding P. A., Sites D. P., Landesman S. Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis. 1986 Apr;153(4):736–742. doi: 10.1093/infdis/153.4.736. [DOI] [PubMed] [Google Scholar]
  13. Heriot K., Hallquist A. E., Tomar R. H. Paraproteinemia in patients with acquired immunodeficiency syndrome (AIDS) or lymphadenopathy syndrome (LAS). Clin Chem. 1985 Jul;31(7):1224–1226. [PubMed] [Google Scholar]
  14. Joller-Jemelka H. I., Joller P. W., Müller F., Schüpbach J., Grob P. J. Anti-HIV IgM antibody analysis during early manifestations of HIV infections. AIDS. 1987 May;1(1):45–47. [PubMed] [Google Scholar]
  15. Kloster B. E., Tomar R. H., Spira T. J. Lymphocytotoxic antibodies in the acquired immune deficiency syndrome (AIDS). Clin Immunol Immunopathol. 1984 Feb;30(2):330–335. doi: 10.1016/0090-1229(84)90066-7. [DOI] [PubMed] [Google Scholar]
  16. Lane H. C., Masur H., Edgar L. C., Whalen G., Rook A. H., Fauci A. S. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983 Aug 25;309(8):453–458. doi: 10.1056/NEJM198308253090803. [DOI] [PubMed] [Google Scholar]
  17. Lange J. M., Coutinho R. A., Krone W. J., Verdonck L. F., Danner S. A., van der Noordaa J., Goudsmit J. Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed) 1986 Jan 25;292(6515):228–230. doi: 10.1136/bmj.292.6515.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Manca N., di Marzo Veronese F., Ho D. D., Gallo R. C., Sarngadharan M. G. Sequential changes in antibody levels to the env and gag antigens in human immunodeficiency virus infected subjects. Eur J Epidemiol. 1987 Jun;3(2):96–102. doi: 10.1007/BF00239745. [DOI] [PubMed] [Google Scholar]
  19. Mayer K. H., Falk L. A., Paul D. A., Dawson G. J., Stoddard A. M., McCusker J., Saltzman S. P., Moon M. W., Ferriani R., Groopman J. E. Correlation of enzyme-linked immunosorbent assays for serum human immunodeficiency virus antigen and antibodies to recombinant viral proteins with subsequent clinical outcomes in a cohort of asymptomatic homosexual men. Am J Med. 1987 Aug;83(2):208–212. doi: 10.1016/0002-9343(87)90686-3. [DOI] [PubMed] [Google Scholar]
  20. Pan L. Z., Cheng-Mayer C., Levy J. A. Patterns of antibody response in individuals infected with the human immunodeficiency virus. J Infect Dis. 1987 Apr;155(4):626–632. doi: 10.1093/infdis/155.4.626. [DOI] [PubMed] [Google Scholar]
  21. Redfield R. R., Wright D. C., Tramont E. C. The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med. 1986 Jan 9;314(2):131–132. doi: 10.1056/NEJM198601093140232. [DOI] [PubMed] [Google Scholar]
  22. Schmidt G., Amiraian K., Frey H., Stevens R. W., Berns D. S. Densitometric analysis of Western blot (immunoblot) assays for human immunodeficiency virus antibodies and correlation with clinical status. J Clin Microbiol. 1987 Oct;25(10):1993–1998. doi: 10.1128/jcm.25.10.1993-1998.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schüpbach J., Haller O., Vogt M., Lüthy R., Joller H., Oelz O., Popovic M., Sarngadharan M. G., Gallo R. C. Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med. 1985 Jan 31;312(5):265–270. doi: 10.1056/NEJM198501313120502. [DOI] [PubMed] [Google Scholar]
  24. Scorza Smeraldi R., Fabio G., Lazzarin A., Eisera N. B., Moroni M., Zanussi C. HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection. Lancet. 1986 Nov 22;2(8517):1187–1189. doi: 10.1016/s0140-6736(86)92197-5. [DOI] [PubMed] [Google Scholar]
  25. Siegal F. P., Lopez C., Hammer G. S., Brown A. E., Kornfeld S. J., Gold J., Hassett J., Hirschman S. Z., Cunningham-Rundles C., Adelsberg B. R. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981 Dec 10;305(24):1439–1444. doi: 10.1056/NEJM198112103052403. [DOI] [PubMed] [Google Scholar]
  26. Stahl R. E., Friedman-Kien A., Dubin R., Marmor M., Zolla-Pazner S. Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma. Am J Med. 1982 Aug;73(2):171–178. doi: 10.1016/0002-9343(82)90174-7. [DOI] [PubMed] [Google Scholar]
  27. Steimer K. S., Puma J. P., Power M. D., Powers M. A., George-Nascimento C., Stephans J. C., Levy J. A., Sanchez-Pescador R., Luciw P. A., Barr P. J. Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria. Virology. 1986 Apr 15;150(1):283–290. doi: 10.1016/0042-6822(86)90289-8. [DOI] [PubMed] [Google Scholar]
  28. Wachter H., Fuchs D., Hausen A., Huber C., Knosp O., Reibnegger G., Spira T. J. Elevated urinary neopterin levels in patients with the acquired immunodeficiency syndrome (AIDS). A preliminary report. Hoppe Seylers Z Physiol Chem. 1983 Sep;364(9):1345–1346. doi: 10.1515/bchm2.1983.364.2.1345. [DOI] [PubMed] [Google Scholar]
  29. Weber J. N., Clapham P. R., Weiss R. A., Parker D., Roberts C., Duncan J., Weller I., Carne C., Tedder R. S., Pinching A. J. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet. 1987 Jan 17;1(8525):119–122. doi: 10.1016/s0140-6736(87)91964-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES